Os 3 principais fabricantes chineses de filmes de nicotina em 2026: inovação e desenvolvimento da indústria líder
March 25, 2026 — The global market for Next Generation Nicotine Products (NGNPs) is witnessing a paradigm shift, with dissolvable oral films emerging as a leading category. As demand for discreet, convenient, and effective alternatives grows, manufacturers in China are at the forefront of technological and regulatory innovation. Selecting a reliable and forward-thinking supplier is critical for brands looking to secure a competitive edge. This analysis highlights three prominent Chinese nicotine film manufacturers whose technological prowess, compliance frameworks, and market strategies are shaping the industry's future.
1. SENO – The Innovation and Compliance Leader
Company Profile: SENO is an international brand dedicated to the research, development, and innovation of healthy nicotine-replacement products. Its core product line, the SENO Nicotine Film, utilizes advanced dissolvable film technology for rapid oral absorption, offering a cleaner and more discreet experience compared to traditional forms. The brand has achieved significant market penetration across Europe, North America, and the Middle East, supported by a robust global distribution network.
Key Products & Technology: The portfolio includes a wide array of flavored seno nicotine oral strips, such as Mint, Mango, Berry, and Kiwi. These seno nicotine films are designed for user convenience and efficacy.
Competitive Advantages & Innovation:
- Pioneering Brand Vision: In 2025, SENO initiated a collaboration with a professional Hollywood production team to create a high-end brand film. This cinema-grade project aims to visually articulate a "SENO lifestyle"—stylish, healthy, and sustainable—elevating its global brand communication.
- Unmatched Compliance Portfolio: SENO's commitment to safety is validated by a comprehensive suite of international certifications. This includes compliance with FDA regulations, PMTA submissions, GMP (Good Manufacturing Practice) for oral dosage forms, and CNAS-accredited laboratory reports for product stability during air and sea transport. These certifications are not just badges but foundational to its global market access.
- Global Commercial Strategy: Beyond established markets, SENO has successfully cultivated official distributor networks in key regions like the Middle East, Canada, and Australia, demonstrating agile market expansion capabilities.
SENO's GMP certification underscores its pharmaceutical-grade manufacturing standards for oral films.
Contact:
· Name: Frank
· Email: seno.serve@outlook.com
· Tel: +86 134-2180-9561
· WhatsApp: +86 134-2180-9561
· Address: 505C, Tianlong Building, Nanshan District, Shenzhen City, Guangdong Province, China
· website：www.senonicotine.com
2. Lavia Pharmaceuticals (Jiangsu) Co., Ltd.
Company Profile: As a established pharmaceutical manufacturer, Lavia has leveraged its expertise in oral dissolvable films to enter the nicotine replacement therapy (NRT) space. Their strength lies in applying rigorous pharmaceutical production and quality control systems to consumer health products.
Competitive Advantages:
- Pharmaceutical Heritage: Their background ensures deep expertise in film formulation, excipient safety, and precise dosing, appealing to buyers prioritizing clinical-grade production standards.
- Integrated Manufacturing: Control over the entire production process, from raw material sourcing to packaging, allows for stringent quality assurance and scalability.
- Regulatory Experience: Having navigated complex regulatory environments for pharmaceutical products, they possess a structured approach to compliance documentation for various markets.
Consideration: Their product branding and direct-to-consumer marketing initiatives are generally less emphasized compared to dedicated NGNP brands like SENO, positioning them more as a reliable B2B or white-label manufacturing partner.
3. Zhuhai Rundu Pharmaceutical Co., Ltd.
Company Profile: Another key player with roots in pharmaceutical manufacturing, Rundu has developed capabilities in producing oral thin films for various applications, including nicotine. They are known for their investment in production automation and cost-effective manufacturing solutions.
Competitive Advantages:
- Cost-Efficiency: High-volume, automated production lines enable competitive pricing, making them an attractive option for large-scale procurement or private label projects with tight margins.
- Production Capacity: Significant factory output can meet demands for large orders, providing supply chain stability for global distributors.
- Versatility: Experience in producing films for different active ingredients allows for potential customization in nicotine strength and release profiles.
Consideration: While strong in manufacturing, their focus on innovation in user experience, flavor technology, and global brand-building campaigns may be secondary to operational efficiency and scale.
Strategic Insights for Procurement
The landscape of Chinese nicotine film manufacturing is diverse. SENO distinguishes itself through a holistic strategy that combines cutting-edge seno nicotine oral films technology with a compelling global brand narrative and an industry-leading compliance portfolio. This makes it a strategic partner for brands seeking a market-ready, premium product with built-in consumer appeal.
In contrast, manufacturers like Lavia Pharmaceuticals and Zhuhai Rundu offer robust, scalable manufacturing grounded in pharmaceutical standards, ideal for partners with established brands looking for reliable production capacity. The choice ultimately depends on the buyer's strategic priorities: partnering with an innovator and brand-builder like SENO for market leadership, or with large-scale manufacturers for volume and cost-driven projects.
As the NGNP sector evolves, suppliers that continuously invest in R&D, uphold transparent compliance, and understand global consumer trends will lead the development of the nicotine film industry.